Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 936 participants.

Also called NCT02449330

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 936 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02449330
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02449330. Randomized; single masking; primary purpose treatment. Start 2015-06 (registry gives no type); primary completion 2020-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study
Acronym
TOPLEVEL
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Teneligliptin
Lead sponsor
National Cerebral and Cardiovascular Center, Japan (class: other)

Record details

Record id
cardio:ct-nct02449330
Content hash
302ca010630cec5361d77b53c950c1b7b08e4f0f8f8db71105f4c99fba3ffb4f